John Nirmalnath
Internal Medicine · Ontario, OHNPI 1225210651
Payments from drug & device makers
Across 481 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$963
- Pfizer$840
- AstraZeneca$666
- Novartis$497
- Lilly USA, LLC$472
- plus $3K from 40 others
What the payments were for
- Food & beverage$7,456100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,471 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $86,628 |
| EliquisApixaban | 32 | $49,707 |
| JanuviaSitagliptin Phosphate | 23 | $30,216 |
| JardianceEmpagliflozin | 30 | $29,701 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $25,556 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $20,641 |
| LinzessLinaclotide | 16 | $18,226 |
| TradjentaLinagliptin | 18 | $17,842 |
| FarxigaDapagliflozin Propanediol | 13 | $16,720 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $15,821 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $9,232 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,406 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $5,719 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,362 |
| Irbesartan | 125 | $2,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $963 | $86,62843 claims |
| MerckJanuvia, Janumet, Janumet Xr | $123 | $65,00458 claims |
| PfizerEliquis | $840 | $49,70732 claims |
| Boehringer IngelheimJardiance, Tradjenta | $209 | $47,54348 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $260 | $27,04732 claims |
| AstraZenecaFarxiga, Symbicort | $666 | $21,08126 claims |
| AbbVieLinzess | $1,101 | $18,22616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Ontario
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.